candewish

GE Is David Hartzell's Highest Conviction Holding - Here's Why

On Nov 23 09:34 AM Trevorr wrote:

> Charles Ortell would have a field day with this article.

Yes, but he would just be wrong again. Ortell doesn't have the
balls to short GE, while Harzell, who knows GE 10 times better
than Ortell can go short or long - and he's saying that anyone
who has an investment horizon beyond the length of their
nose should be going long. Who do you believe - Ortell who
still claims GE is a $2 stock or Harzell?

U.S. Market: So Much Stupidity in Such Little Time

My pessimism regarding current affairs is rooted in the obvious dumbing down of America which has produced the tiny minds that think all of our problems are due to Republicans. Would those pea brains please re-read this article?

Wind Power: What We Can Learn from Denmark

Denmark is a small country and its entire grid experiences similar wind speeds. That's not the case in the US.

Roche Covets Genentech for Good Reason

The premium Roche offered for the purchase of outstanding shares
was only 11%, not 44% as stated above. Further Roche's $89/share
offer was tendered when the market price of $80/share was regarded
by most DNA investors as well below Genentech's fair value.
Wall Street's response to Roche's offer was, "Does anyone take those
penny pinching Swiss seriously??"

Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile

Fortunately, neither the FDA nor the physicians who will use Advexin are as dense as this author.